Telix Pharmaceuticals Limited income statement TLX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Telix Pharmaceuticals Limited reported revenue of $803.8 million. It recorded a net loss of $7.1 million. Operating income came to $29.8 million, an operating margin of 3.7%. Diluted earnings per share were -$0.02.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Revenue
804
Cost of revenue
377
Gross profit
426
Research and development
171
Selling, general and administrative
96
Operating income
30
Pretax income
-5
Income tax
2
Net income
-7
Basic EPS
-0.02
Diluted EPS
-0.02
Weighted average shares, basic
338
+2.0%
Weighted average shares, diluted
338
-2.1%
Other measures
Depreciation and amortization
22
EBITDA
51
Interest coverage
164.51x
Margins
Gross margin
53.05%
Operating margin
3.70%
Pretax margin
-0.66%
Profit margin
-0.89%
EBITDA margin
6.38%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TLX (Nasdaq), TLPPF (OTC)
Fiscal year ends
December 31
Incorporated in
Australia
Headquarters
North Melbourne, Australia
SEC filer status
Large accelerated filer
SEC CIK
2007191

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.